Estamos comprometidos en contribuir en la investigación de nuevos medicamentos que ayuden a mejorar el entendimiento de las enfermedades neurológicas.
Favor de referirse a algunos de nuestras investigaciones y presentaciones:
"Clinical features of Multiple Sclerosis in Puerto Rico"
"Low Serum levels of vitamin D in MS patients in Puerto Rico"
"Proteomic Biomarkers of PBMCS from MS patients with vitamin D deficiency"
"HLA en pacientes con esclerosis múltiple en Puerto Rico"
"Clinical Experience with natalizumab in Multiple Sclerosis Center in Puerto Rico"
Favor de referirse a algunos de nuestros estudios en progreso:
“Biogen Idec Protocol 101MS402 (TYGRIS) TYSABRI® Global Observational Program in Safety”
“Biogen Idec Protocol 109MS303-Biogen Idec A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis”
“Biogen Idec Protocol 101JC402 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri - STRATIFY2”
“Novartis Protocol CFTY720DUS01 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)”
“Novartis Protocol CFTY720D2403 Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with Fingolimod once daily or treated with another approved disease-modifying therapy”